1:16 PM
 | 
Jul 07, 2017
 |  BC Week In Review  |  Company News  |  Deals

Effector combining EFT508 and Bavencio

Effector Therapeutics Inc. (San Diego, Calif.) will conduct an open-label, Phase II trial evaluating EFT508 with or without PD-L1 inhibitor Bavencio avelumab from Merck...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >